Zobrazeno 1 - 7
of 7
pro vyhledávání: '"O V, Stakhina"'
Autor:
G A Gusarova, A G Turkina, E V Domracheva, L Yu Tikhonova, M O Egorova, T I Kolosheynova, O V Stakhina, I S Nemchenko, M V Vakhrusheva, E Yu Chelysheva, E S Zakharova, S R Goryacheva, M A Sokolova, S V Kuznetsov, N A Afanas'eva, N D Khoroshko
Publikováno v:
Современная онкология, Vol 12, Iss 1, Pp 38-42 (2010)
Externí odkaz:
https://doaj.org/article/2378899bf7fc419d80c98cdefa5a74c9
Autor:
Anna Grigor'evna Turkina, Elena Vasil'evna Domracheva, Aleksandra Valer'evna Vorontsova, Elena Aleksandrovna Aseeva, Ol'ga Yur'evna Vinogradova, Ol'ga Veniaminovna Stakhina, Galina Anatol'evna Gusarova, Ol'ga Arkad'evna Dyagileva, Elena Aleksandrovna Semenova, Marina Vasil'evna Vakhrusheva, Tamara Ivanovna Kolosheynova, Evgeniy Mikhaylovich Abakumov, Ekaterina Yur'evna Chelysheva, Svetlana Rudol'fovna Goryacheva, Tat'yana Vladimirovna Ivanova, Elena Stanislavovna Zakharova, Lyubov' Yur'evna Kolosova, Adel' Vladimirovna Zakharova, Irina Nikolaevna Naumova, Larisa Vladimirovna Dyachenko, Sergey Mikhaylovich Kulikov, Lidiya Grigor'evna Kovaleva, Nina Dmitrievna Khoroshko, A G Turkina, E V Domracheva, A V Vorontsova, E A Aseeva, O Yu Vinogradova, O V Stakhina, G A Gusarova, O A Dyagileva, E A Semenova, M V Vakhrusheva, T I Kolosheinova, E M Abakumov, E Yu Chelysheva, S R Goryacheva, T V Ivanova, E S Zakharova, L Yu Kolosova, A V Zakharova, I N Naumova, L V Dyachenko, S M Kulikov, L G Kovaleva, N D Khoroshko
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 29-36 (2009)
Aim. To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK). Material and methods. A total of 386 patients with
Externí odkaz:
https://doaj.org/article/ede8cfd0b762457a94075ebaf7be705f
Autor:
Ol'ga Yur'evna Vinogradova, Anna Grigor'evna Turkina, Aleksandra Valer'evna Vorontsova, Ekaterina Yur'evna Chelysheva, Galina Anatol'evna Gusarova, S V Kuznetsov, Svetlana Rudol'fovna Goryacheva, Manana Aleksandrovna Sokolova, Evgeniy Mikhaylovich Abakumov, Ol'ga Veniaminovna Stakhina, Elena Vasil'evna Domracheva, Andrey Vital'evich Misyurin, Nina Dmitrievna Khoroshko, O Yu Vinogradova, A G Turkina, A V Vorontsova, E Yu Chelysheva, G A Gusarova, S R Goryacheva, M A Sokolova, E M Abakumov, O V Stakhina, E V Domracheva, A V Misyurin, N D Khoroshko
Publikováno v:
Терапевтический архив, Vol 81, Iss 7, Pp 41-46 (2009)
Aim. To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. Material and methods. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2
Externí odkaz:
https://doaj.org/article/52408b4dd35a4033bdaadedff47754a6
Publikováno v:
Терапевтический архив, Vol 82, Iss 2, Pp 59-61 (2010)
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is general
Externí odkaz:
https://doaj.org/article/3aaf491b1fc343ebaddd82327cdb074e
Publikováno v:
Terapevticheskii arkhiv. 82(2)
The use of imatinib mesylate (Glivec) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a4c1fc8afcf350bc7577d950eb13f3c
https://pubmed.ncbi.nlm.nih.gov/20387680
https://pubmed.ncbi.nlm.nih.gov/20387680
Autor:
O Iu, Vinogradova, A G, Turkina, A V, Vorontsova, E Iu, Chelysheva, G A, Gusarova, S V, Kuznetsov, S R, Goriacheva, M A, Sokolova, E M, Abakumov, O V, Stakhina, E V, Domracheva, A V, Misiurin, N D, Khoroshko
Publikováno v:
Terapevticheskii arkhiv. 81(7)
To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.Lethal outcomes during d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c0521ccb30ec2e7841dcc85626135d06
https://pubmed.ncbi.nlm.nih.gov/19708572
https://pubmed.ncbi.nlm.nih.gov/19708572
Publikováno v:
Terapevticheskii arkhiv. 80(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a2b301b8c1ba850d14780a43e5d45e44
https://pubmed.ncbi.nlm.nih.gov/18763601
https://pubmed.ncbi.nlm.nih.gov/18763601